DK1807083T3 - Anvendelse af pirlindol til behandling af lidelser, der er kendetegnet ved proliferation af T-lymphocyter og/eller hyperproliferation af keratinocyter, især atopisk dermatitis og psoriasis - Google Patents

Anvendelse af pirlindol til behandling af lidelser, der er kendetegnet ved proliferation af T-lymphocyter og/eller hyperproliferation af keratinocyter, især atopisk dermatitis og psoriasis

Info

Publication number
DK1807083T3
DK1807083T3 DK05798339.7T DK05798339T DK1807083T3 DK 1807083 T3 DK1807083 T3 DK 1807083T3 DK 05798339 T DK05798339 T DK 05798339T DK 1807083 T3 DK1807083 T3 DK 1807083T3
Authority
DK
Denmark
Prior art keywords
pirlindole
hyperproliferation
keratinocytes
treatment
psoriasis
Prior art date
Application number
DK05798339.7T
Other languages
English (en)
Inventor
Stefan Bell
Original Assignee
Switch Biotech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Switch Biotech Llc filed Critical Switch Biotech Llc
Application granted granted Critical
Publication of DK1807083T3 publication Critical patent/DK1807083T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK05798339.7T 2004-11-02 2005-11-02 Anvendelse af pirlindol til behandling af lidelser, der er kendetegnet ved proliferation af T-lymphocyter og/eller hyperproliferation af keratinocyter, især atopisk dermatitis og psoriasis DK1807083T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04025961A EP1688161A1 (en) 2004-11-02 2004-11-02 Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
PCT/EP2005/011697 WO2006048242A2 (en) 2004-11-02 2005-11-02 Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis

Publications (1)

Publication Number Publication Date
DK1807083T3 true DK1807083T3 (da) 2011-06-06

Family

ID=34927197

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05798339.7T DK1807083T3 (da) 2004-11-02 2005-11-02 Anvendelse af pirlindol til behandling af lidelser, der er kendetegnet ved proliferation af T-lymphocyter og/eller hyperproliferation af keratinocyter, især atopisk dermatitis og psoriasis

Country Status (10)

Country Link
US (1) US20080254106A1 (da)
EP (2) EP1688161A1 (da)
JP (1) JP2008518891A (da)
AT (1) ATE503482T1 (da)
AU (1) AU2005300727B2 (da)
CA (1) CA2585536A1 (da)
DE (1) DE602005027232D1 (da)
DK (1) DK1807083T3 (da)
ES (1) ES2363019T3 (da)
WO (1) WO2006048242A2 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis
EP2340254B8 (en) 2008-09-15 2014-05-21 Biovista, Inc. Compositions and methods for treating epilepsy
JP2012512165A (ja) * 2008-12-11 2012-05-31 バイオヴィスタ，インコーポレイテッド 四環系ピラジノインドールを用いた多発性硬化症の治療方法
EP2547323B1 (en) 2010-03-17 2016-01-27 Novaliq GmbH Pharmaceutical composition for treatment of increased intraocular pressure
EP2444063A1 (en) 2010-10-20 2012-04-25 Novaliq GmbH Liquid pharmaceutical compositions for the delivery of active ingredients
EP2462921A1 (en) 2010-11-11 2012-06-13 Novaliq GmbH Liquid pharmaceutical compositions for the treatment of a posterior eye disease
JP2014511393A (ja) * 2011-03-07 2014-05-15 セルジーン コーポレイション イソインドリン化合物を用いた疾患の治療方法
CN108283623A (zh) 2011-05-25 2018-07-17 诺瓦利克有限责任公司 基于半氟化烷烃类的外用药物组合物
WO2012160180A2 (en) * 2011-05-25 2012-11-29 Novaliq Gmbh Pharmaceutical composition for administration to nails
WO2013070526A1 (en) 2011-11-09 2013-05-16 Teikoku Pharma Usa, Inc. Methods for the treatment of skin neoplasms
WO2013130422A1 (en) 2012-02-27 2013-09-06 Biovista, Inc. Compositions and methods for treating mitochondrial diseases
RU2662564C2 (ru) * 2012-07-04 2018-07-26 ЗЗ Байотек ЛЛС Лечение воспалительных заболеваний кожи
KR101874219B1 (ko) 2012-09-12 2018-07-03 노바리크 게엠베하 부분불소화 알칸의 혼합물을 포함하는 조성물
AU2013314303B2 (en) 2012-09-12 2018-01-18 Novaliq Gmbh Semifluorinated alkane compositions
JP6058156B2 (ja) * 2012-12-19 2017-01-11 ポリケム・エスエイ アトピー性皮膚炎を処置するためのピドチモドの使用
KR102232198B1 (ko) * 2014-05-09 2021-03-26 테크니메데 소시에다데 테크니코-메디시날 에스.에이. 의약으로서 사용되기 위한 (r)-펄린돌 및 약학적으로 허용 가능한 그의 염
TN2016000498A1 (en) * 2014-05-09 2018-04-04 Tecnimede Sociedade Tecnico Medicinal S (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine.
AU2014393487B2 (en) 2014-05-09 2020-01-02 Tecnimede Sociedade Tecnico-Medicinal S.A. Pharmaceutically acceptable salts of pirlindole enantiomers for use in medicine
US20170087100A1 (en) 2015-09-30 2017-03-30 Novaliq Gmbh Semifluorinated compounds and their compositions
US11154513B2 (en) 2015-09-30 2021-10-26 Novaliq Gmbh Semifluorinated compounds
WO2017220625A1 (en) 2016-06-23 2017-12-28 Novaliq Gmbh Topical administration method
ES2969758T3 (es) 2016-09-22 2024-05-22 Novaliq Gmbh Composiciones farmacéuticas para usar en la terapia de la blefaritis
JP6869336B2 (ja) 2016-09-23 2021-05-12 ノバリック ゲーエムベーハー シクロスポリンを含む眼科用組成物
KR102351816B1 (ko) 2017-04-21 2022-01-17 노바리크 게엠베하 요오드 조성물
EP3621601A1 (en) 2017-05-12 2020-03-18 Novaliq GmbH Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
CA3076776A1 (en) 2017-09-27 2019-04-04 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
JP7353292B2 (ja) 2018-03-02 2023-09-29 ノバリック ゲーエムベーハー ネビボロールを含む医薬組成物
ES2950878T3 (es) 2018-09-27 2023-10-16 Dermaliq Therapeutics Inc Formulación de protección solar de uso tópico
CN112823020A (zh) 2018-10-12 2021-05-18 诺瓦利克有限责任公司 用于治疗干眼病的眼用组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY110603A (en) * 1993-05-27 1998-08-29 Novartis Ag Tetrahydropyran derivatives
US5922341A (en) * 1997-10-28 1999-07-13 Vivus, Incorporated Local administration of pharmacologically active agents to treat premature ejaculation
US6514696B1 (en) * 1997-11-13 2003-02-04 The Regents Of The University Of California Transcriptionally regulated G protein-coupled receptor G2A
JP2005504043A (ja) * 2001-08-10 2005-02-10 パラチン テクノロジーズ インク． 生物学的に活性な金属ペプチド類のペプチド模倣体類
DE60216300T2 (de) * 2001-09-21 2007-06-28 Schering Corp. Behandlung von xanthom mittels azetidinon-derivate als hemmer der sterol absorption
US7038085B2 (en) * 2002-10-25 2006-05-02 Collegium Pharmaceutical, Inc. Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof
DE50304744D1 (de) * 2003-04-28 2006-10-05 Biofrontera Bioscience Gmbh Verwendung von Riluzole kombiniert mit geeigneten Hilfs-und Zusatzstoffen zur Behandlung von Krankheiten, die durch eine Hyperproliferation von Keratinozyten gekennzeichnet sind, insbesondere Neurodermitis und Psoriasis
EP1688161A1 (en) * 2004-11-02 2006-08-09 Switch Biotech Aktiengesellschaft Use of pirlindole for the treatment of diseases which are characterized by proliferation of t-lymphocytes and/or hyperproliferation of keratinocytes in particular atopic dermatitis and psoriasis

Also Published As

Publication number Publication date
ES2363019T3 (es) 2011-07-18
EP1688161A1 (en) 2006-08-09
EP1807083A2 (en) 2007-07-18
JP2008518891A (ja) 2008-06-05
CA2585536A1 (en) 2006-05-11
AU2005300727B2 (en) 2010-07-15
AU2005300727A1 (en) 2006-05-11
US20080254106A1 (en) 2008-10-16
WO2006048242A3 (en) 2006-11-09
DE602005027232D1 (de) 2011-05-12
WO2006048242A2 (en) 2006-05-11
ATE503482T1 (de) 2011-04-15
EP1807083B1 (en) 2011-03-30

Similar Documents

Publication Publication Date Title
DK1807083T3 (da) Anvendelse af pirlindol til behandling af lidelser, der er kendetegnet ved proliferation af T-lymphocyter og/eller hyperproliferation af keratinocyter, især atopisk dermatitis og psoriasis
CO6210752A2 (es) Compuestos biciclicos y uso como antidiabeticos
MA32811B1 (fr) Nouveaux composés
TW200602808A (en) Functionalized photoinitiators
WO2009003998A3 (en) Antiproliferative compounds based on 5-membered heterocycles
DE602004030464D1 (de) Methode zur produktion und evaluierung der zytotoxizität von kir2dl nk-rezeptor antikörpern
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
WO2006027346A3 (en) Novel pyrazolopyrimidines
UA102065C2 (en) Substituted 4-aryl-1,4-dihydro-1,6-naphthyridinamides and use thereof
WO2006008028A8 (de) Neue 6-formyl-tetrahydropteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel, u.a. gegen krebs
ATE547107T1 (de) Verwendung von selenhefe in der behandlung von alzheimers krankheit
UY31484A1 (es) Piperidinas heteroaril-sustituidas
ATE489371T1 (de) Benzamidglucokinaseaktivatoren
ATE523510T1 (de) Substituierte 4-aryl-1,4-dihydro-1,6- naphthyridine und ihre verwendung
MA32505B1 (fr) 5-alcynyl-pyrimidines
NO20075368L (no) Antiinflammatoriske modaliteter
TW200726763A (en) Novel compound
UA94080C2 (ru) Ациклически-замещенные производные фуропиримидина и их применение для лечения сердечно-сосудистых заболеваний
ATE524463T1 (de) 4-chromenonyl-1,4-dihydropyridincarbonitrile und ihre verwendung
ATE500253T1 (de) 3-cyano-5-thiazaheteroaryl-dihydropyridine und ihre verwendung zur behandlung kardiovaskulärer erkrankungen
WO2007115929A8 (de) Thiazolyl-dihydro-quinazoline
DE502005005652D1 (de) Heterocyclyl-substituierte nonadepsipeptide
ATE496047T1 (de) Phenylen-bis-oxazolidin-derivate und ihre verwendung als antikoagulantien
ATE527996T1 (de) Medizinische verwendung von 3-(2,2,2- trimethylhydrazinium)propionat-orotat
ATE435868T1 (de) Homogemcitabine